A Study Utilizing Escitalopram in Glioma Patients

Glioma is a cancer of glial cells, a class of tissue supporting neuronal function in the brain. As many as 85% of glioma patients experience cognitive impairment. This is not only from direct tumor involvement, but also from therapy such as cranial radiation and chemotherapy, which degrades neuronal function. There is evidence that serotonin selective reuptake inhibitors (SSRIs), such as escitalopram, improve cognition or prevent cognitive decline and may also improve outcomes critical to overall survival including functional independence, psychosocial stability, and quality of life. This pilo

Trial Details

NCT ID
NCT03728673
Phase
PHASE2
Sponsor
University of Nebraska
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Escitalopram Oral Capsules
Locations (sample)
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Pathologically proven diagnosis of Grade IV glioma
  • Newly diagnosed disease to receive chemotherapy and/or radiation
  • Performance status Eastern Cooperative Oncology Group (ECOG) 0-2 or equivalent
  • 19 years of age or older

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →